

Review

Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years



Bo Liu, Xin Wen, Canhua Huang*, Yuquan Wei

State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China

ARTICLE INFO

Article history:

Received 5 May 2013

Received in revised form 18 June 2013

Accepted 21 June 2013

Available online 29 June 2013

Keywords:

Hepatitis B virus

HBx protein

Hepatocellular carcinoma

In vivo model

HBV therapy

ABSTRACT

Hepatitis B virus (HBV) is a well-known hepadnavirus with a double-stranded circular DNA genome. Although HBV was first described approximately 50 years ago, the precise mechanisms of HBV infection and effective therapeutic strategies remain unclear. Here, we focus on summarizing the complicated mechanisms of HBV replication and infection, as well as genomic factors and epigenetic regulation. Additionally, we discuss *in vivo* models of HBV, as well as diagnosis, prevention and therapeutic drugs for HBV. Together, the data in this 50-year review may provide new clues to elucidate molecular mechanisms of HBV pathogenesis and shed new light on the future HBV therapies.

© 2013 Elsevier Ltd. All rights reserved.

Contents

1. Introduction.....	1988
2. Hepatitis B virus (HBV) replication and infection.....	1988
3. Molecular mechanisms of HBV.....	1988
3.1. Core regulators in HBV and hepatocellular carcinoma.....	1988
3.2. HBV genotype.....	1990
3.3. MicroRNAs in HBV and hepatocellular carcinoma (HCC).....	1990
3.4. Single nucleotide polymorphisms (SNPs) in HBV.....	1990
3.5. Epigenetic factor in HBV: DNA methylation.....	1991
4. <i>In vivo</i> models in HBV.....	1991
4.1. Mouse models.....	1991
4.2. Chimpanzee models.....	1991
4.3. Woodchuck models.....	1991
4.4. Tree shrews models.....	1991

Abbreviations: AFP, α -fetoprotein; ALDH1, aldehyde dehydrogenase 1; ALL, lymphoblastic leukemia; ALT, alanine aminotransferase; AR, androgen receptor; AST, aspartate aminotransferase; cccDNA, covalently closed circular DNA; CDH1, cadherin-1; C/EBP- β , CCAAT enhancer binding protein β ; CHB, chronic hepatitis B; CIITA, class II transactivator; CP, core promoter; CREB, cyclic adenosine monophosphate (cAMP) response element-binding protein; CRHR2, corticotropin-releasing hormone receptor 2; CTLs, CD8T lymphocytes; CXCR1, chemokine (C-X-C motif) receptor 1; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated; DTP, diphtheria-tetanus-pertussis; FAK, focal adhesion kinase; FDA, Food and Drug Administration; FXRA, farnesoid X receptor alpha; HB, hepatitis B; HBeAg, hepatitis B e antigen; HBcAg, hepatitis B core antigen; HBIG, hepatitis B immune globulin; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HBx, hepatitis B X protein; HCC, hepatocellular carcinoma; HDAC1, histone deacetylase 1; hnRNP K, heterogeneous nuclear ribonucleoproteins K; HO-1, Heme oxygenase-1; IFNAR1, type I interferon (IFN- α /beta) receptor 1; IL, interleukin; IFN- α , interferon alpha; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; miRNA, microRNA; MMF, macrophagic myofasciitis; MTA1, metastasis-associated protein 1; NHP, non-human primates; OPN, osteopontin; ORFs, open reading frames; PC, precore; PKC, protein kinase C; PEG, polyethylene glycol; PH, portal hypertension; PP1, protein phosphatase 1; PPIs, protein-protein interactions; RNAi, RNA interference; SNPs, single nucleotide polymorphisms; SPP1, secreted phosphoprotein-1; STAT, signal transducer and activator of transcription; TBP, TATA binding protein; TGF, transforming growth factor; TNF, tumor necrosis factor; WHV, woodchuck hepatitis virus; 5-LOX, 5-lipoxygenase.

* Corresponding author. Tel.: +86 13258370346; fax: +86 28 85164060.

E-mail address: hcanhua@hotmail.com (C. Huang).

5.	Therapeutic applications in HBV.....	1992
5.1.	HBV diagnosis and prevention.....	1992
5.2.	Current HBV therapeutic drugs.....	1992
5.2.1.	Interferons.....	1993
5.2.2.	Nucleos(t)ide analogs.....	1993
5.3.	Current HBV drugs.....	1993
5.4.	Combination therapeutic strategies.....	1994
6.	Conclusions and future perspectives.....	1994
	Acknowledgements.....	1994
	References.....	1994

1. Introduction

Hepatitis B virus (HBV) is a member of the hepadnaviridae virus family, whose replication is not directly cytopathic (Liaw and Chu, 2009). However, HBV infection, a global health problem, can lead to a wide spectrum of liver disease ranging from acute to chronic viral hepatitis, which often develops into liver cirrhosis and even hepatocellular carcinoma (HCC) (Urban et al., 2010).

In early 1966, “Australia antigen” (Au) was reported to be linked to liver diseases and subsequently confirmed to be a marker of HBV infection (Ganem and Prince, 2004; Blumberg et al., 1965). In 1979, the HBV genome sequence was revealed and the gene sequence of the hepatitis B virus surface antigen (HBsAg) was identified (Galibert et al., 1979; Valenzuela et al., 1979). In 1981, hepatitis B x protein (HBx), one of the most important HBV proteins, was first identified, while in 1986, Pre-S1 coded sequences in the envelope proteins of HBV were found to be involved in the specific attachment of HBV to liver cells (Neurath et al., 1986; Fattovich et al., 2008). Sodium taurocholate cotransporting polypeptide (Ntcp) was demonstrated to be a functional receptor for HBV in 2012 (Yan et al., 2012). Various vaccines and two types of drugs, including interferons and nucleos(t)ide analogs, have been developed to treat HBV infection. A timeline in this paper covers the history of HBV, focusing on a series of key events that may lead to further understanding of HBV (Fig. 1).

2. Hepatitis B virus (HBV) replication and infection

Viral proteins of clinical importance in HBV include the envelope protein, hepatitis B surface antigen (HBsAg), hepatitis B core antigen (HBcAg), and hepatitis B e antigen (HBeAg) (Seeger et al., 1986). The first step in HBV replication involves a non-cell-type-specific primary attachment followed by irreversible binding of the virus to a specific receptor on the plasma membrane of hepatocytes (Schmitt et al., 1999; Bardens et al., 2011). Once in the cytoplasm, the capsid delivers its relaxed circular DNA (rcDNA) previously contained within the virion, into the nucleus by using nuclear pore complexes (NPC) (Kann et al., 2007). Upon arriving in the nucleus, viral rcDNAs, which are incomplete circles, are converted into a covalently closed circular form (cccDNA) (Ng et al., 2005). Unlike the provirus DNA of retroviruses, the cccDNA does not need to be integrated into the host genome, and the cccDNA pool appears to be stable in the absence of cell division (Dandri et al., 2002; Zoulim, 2005; Beck and Nassal, 2007; Lutgehetmann et al., 2010). Subsequently, pgRNA is packaged into newly formed capsids, the crucial step in HBV replication. Assembly and release of the DNA-containing nucleocapsids seem to be required to recruit the nucleocapsid to the site of budding by a balanced co-expression of small and large envelope proteins (Newbold et al., 1995; Liang, 2009). After concomitant degradation of the pgRNA, a single-stranded DNA of minus polarity and a complementary plus-strand DNA are synthesized to form the HBV genome (rcDNA) (Mason et al., 2005). Finally, virions are assembled on and

bud from the endoplasmic reticulum (ER) membrane through the engulfing of rcDNA-containing capsids by ER membranes that contain viral envelope proteins (Perlman and Hu, 2003) (Fig. 2).

The individual course of HBV infection is determined by the interaction between virus replication and the host immune response. It has been widely accepted that HBV infection goes through different, usually successive phases: (1) immune tolerance, (2) HBeAg-positive chronic hepatitis B (CHB) (immune clearance), (3) immune control (low or non-replicative), and (4) HBeAg negative CHB (immune escape) (Chu et al., 2002a; Iloeje et al., 2012). The four phases have been identified on the basis of specific biochemical, serological and virological characteristics, including serum aminotransferase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), HBV DNA and HBsAg protein levels and HBeAg serostatus (Fig. 2).

3. Molecular mechanisms of HBV

3.1. Core regulators in HBV and hepatocellular carcinoma

Core regulators such as hepatitis B X protein (HBx) have been identified and explored in HBV pathogenesis (Fig. 3A). HBx, a small 16.5-kDa polypeptide of 154 amino acids, is well characterized to mediate the pathological effects of HBV (Xie et al., 2012; Cougot et al., 2012). In the cytoplasm, HBx modulates many host processes directly or indirectly, while in the nucleus, this viral protein can stimulate the activity of numerous transcription factors and interact with various members of the general transcription machinery complex (Sung et al., 2009; Zhang et al., 2010; Lucifora et al., 2011). HBx can activate genes targeted by the transcription factor cyclic adenosine monophosphate response element-binding protein (CREB), which is then recruited to HBV DNA in infected cells (Zhang et al., 2013; Murakami, 2001). In addition, HBx can affect several key signaling pathways, such as the Ras-Raf-MAPKs, SAPK/JNK, JAK/STATs and protein kinase C (PKC) pathways (Ma et al., 2011). Activation of the ERK/NF- κ B pathway by HBx can lead to the transactivation of interleukin-23 (IL-23), a critical protein in many chronic inflammatory diseases including HB (Xia et al., 2012). Several putative nuclear targets of HBx have also been identified, including CREB transcriptional factors, RNA polymerase subunit RPB5, p53, and TATA binding protein (TBP) (Qadri et al., 2011). Additionally, HBx can induce tumor necrosis factor (TNF)- α -mediated apoptotic destruction of liver cells or directly induce the expression of transforming growth factor (TGF)- β 1 (Lee et al., 2001). Recently, new interactions between HBx and HVDAC3 and a novel subcellular distribution of HBx have been identified (Rahmani et al., 2000). Some specific targets, such as aldehyde dehydrogenase 1 (ALDH1) and two calcium ion-binding proteins, S100A6 and S100A4, can be hypermethylated by HBx (Kim et al., 2006). HBx can also repress apoptosis by inhibiting the p53-mediated pathway or caspase-independent pathways involving the repression of mitochondrion-to-nucleus translocation of AIF. HBx may activate the autophagic pathway in HepG-2 cells via the




Fig. 1. Timeline: a history of hepatitis B virus.

PI3K-Akt-mTOR pathway or up-regulation of Beclin-1 expression (Tang et al., 2009; Liu et al., 2012b; Wang et al., 2013). Heme Oxygenase-1 (HO-1) can elicit its anti-viral effect directly in hepatocytes and inhibit HBV infection efficiently at a posttranscriptional step by reducing the stability of HBV core protein (Protzer et al., 2007). Activation of signal transducer and activator of transcription

(STAT) family members is critical for regulation of some key cellular processes in HBV infection (Gao et al., 2012). Moreover, cytotoxic CD8T lymphocytes (CTLs) can play a pivotal role in the control of HBV infection (Hofmeyer et al., 2011). Specifically, accumulation of the large envelope protein in the ER of hepatocytes is associated with predisposition to transformation in transgenic animal studies




Fig. 2. Different stages of HBV replication and infection.




Fig. 3. Regulatory mechanisms of HBV infection. (A) HBV regulation network; (B) HBx interactome and HCC-related modulators; (C) MicroRNAs, genomic factors and epigenetic regulation.

and with severe fulminant hepatitis in human (Chisari et al., 1989). Additionally, integrated HBV DNA can encode a carboxyl terminally truncated protein (Fig. 3B).

HBV core promoter (CP) mutations are known to be associated with an increased risk of HCC due to ubiquitin-mediated proteasomal degradation (Huang et al., 2011). HBx does not bind directly to DNA but causes transcriptional activation through interaction with nuclear transcription factors and modulation of cytoplasmic signaling pathways, including Ras, Raf, c-JUN, Mitogen-activated protein kinases (MAPKs), NF- κ B, Janus kinase (JAK)-STAT, focal adhesion kinase (FAK), PKC, and metastasis-associated protein 1 (MTA1) (Feitelson and Lee, 2007). Additionally, HBx can up-regulate the expression of Notch-1, Jagged-1 and Hes-1 at the transcriptional level, suggesting that HBx may promote the progression to HCC by activating the Notch pathway (Wang et al., 2012b). HBx can stabilize AIB1 protein, and in conjunction, these proteins promote cell invasiveness in HCC (Liu et al., 2012a). HBx can activate PAK1, which may promote HCC progression in chronic HBV infection (Xu et al., 2012). The complex cell context-dependent interactions between p53 family members and HBx in the regulation of apoptosis may be essential in HBV-induced HCC therapy (Knoll et al., 2011) (Fig. 3B).

3.2. HBV genotype

Of note, HBV can be classified into 10 genotypes, named A–J, with distinct prevalence of certain genotypes in different geographical regions (Chu and Lok, 2002b). There is increasing evidence that HBV genotypes may correlate with both clinical outcomes of chronic HBV infection and response to treatment. Genotype A is most common in the United States and Northern Europe, B and C in Asia, E in Africa, F/H in Central and South America and D/G are scattered worldwide (Orito et al., 2001; Sumi et al., 2003). Most studies on HBV genotypes have been carried out in Asia, where studies have been restricted to comparisons of patients infected with

genotypes B and C (Wang et al., 2010a). It is widely accepted that different HBV genotypes may be associated with different rates of progression from acute to chronic HBV infection (Chen et al., 2007) (Fig. 3C).

3.3. MicroRNAs in HBV and hepatocellular carcinoma (HCC)

MicroRNAs (miRNAs) are small and non-coding RNAs ~22 nucleotides (nt) in length and may regulate approximately 30% of human gene expression (Fu et al., 2012). Recently, numerous studies have highlighted miRNAs as new regulators in HBV. MiR-155 can activate the HBV enhancer II as well as bind to the core and S promoters (Wang et al., 2009). Inhibition of miR-372 results in induction of phosphorylation of CREB and dissociation of CREB from the promoter (Wang et al., 2010b). In addition, miR-1 is able to enhance HBV core promoter transcription activity. miR-19b, miR-122 and miR-223 are associated with HBsAg positive immunoprecipitates, while miR-16 and miR-20a can be detected in control immunoprecipitates (Pedersen et al., 2007). Moreover, hsa-miR-125a-5p, an miRNA expressed in human liver, can down-regulate expression of the HBV S gene (Lakner et al., 2011).

Several reports have examined miRNA expression profiles in human HCC tissues by miRNA-based microarray or sequencing and analyzed the miRNA alteration link to HBV infection (Ladeiro et al., 2008). Recent studies have also reported that human serum/plasma contains a number of stable miRNAs that could potentially serve as a novel noninvasive biomarker for disease diagnosis (Chen et al., 2008). HB can also progress into liver cirrhosis that causes predisposition to HCC, and a number of miRNAs have been found during HBV-related cirrhotic stages (Braconi and Patel, 2008) (Fig. 3C).

3.4. Single nucleotide polymorphisms (SNPs) in HBV

The most common type of sequence variations in the human genome is the single nucleotide polymorphisms (SNPs), the

stable substitution of a single base (Carlson et al., 2003). Accumulated evidence in molecular genetics indicates that SNPs in tumorigenesis-related genes are associated with susceptibility to HBV and HCC, especially in Asian countries. The SNPs in chemokine (C-X-C motif) receptor 1 (CXCR1) rs2234671 may associate with chronic HBV infection (Almajhdi et al., 2013). Moreover, the SNPs in rs9277535 non-GG genotype are associated with a high likelihood of spontaneous HBsAg seroclearance (Xie et al., 2013). A single-nucleotide polymorphism (rs2910164) within the miR-146a gene is associated with the risk of acquiring acute-on-chronic hepatitis B liver failure (Cheng et al., 2013). IL-28B rs12979860C/T polymorphism may also confer symptomatic specificity in the progress and extent of hepatitis B infection (Chen et al., 2012). Moreover, gene variants of IL10 and IL20 polymorphisms can influence HBV infection outcome (Truelove et al., 2008). The polymorphisms in cytokine and toll-like receptors (TLR)-2/3 genes have also been found to be related to hepatitis B infection (Wang et al., 2012e). The SNPs in the regulated and normal T cell expressed and secreted (RANTES) gene are associated with HBV, and the SNPs (C-1350T and G-944C) in class II transactivator (CIITA) promoter IV, which plays a pivotal role in immune response, are associated with persistent HBV infection (Zhang et al., 2007; Al-Qahtani et al., 2012). The type I interferon (IFN-alpha/beta) receptor 1 (IFNAR1) 19158C/G polymorphism has been found to be primarily associated with chronic HBV infection (Zhou et al., 2009) (Fig. 3C).

3.5. Epigenetic factor in HBV: DNA methylation

Epigenetics refers to all heritable changes in gene expression and chromatin organization that are independent of the actual DNA sequence, including DNA methylation, RNAs, and histone (chromatin) modifications. DNA methylation is the predominant mechanism employed to inactivate relevant genes in HCC. Thus, a role for epigenetic changes in the regulation of viral protein production likely reflects viral adaptation to host cells (Tong et al., 2009). When HBV infects liver tissue, methylation density varies considerably. In many cases, methylation levels are low and these low levels can affect viral protein production. In addition, methylation of cccDNA affects protein production, and methylated cccDNA can be found in human tissues (Vivekanandan et al., 2008) (Fig. 3C).

4. In vivo models in HBV

4.1. Mouse models

The transgenic mouse model is established by introduction of HBV DNA into the mouse germ line, in particular the HBx gene, and has been studied in HCC with a transgenic CD1 mouse model (Heindryckx et al., 2009; Kim et al., 2009). HBx can promote the growth of Huh7 xenograft tumors in mice. Multifocal areas of altered hepatocytes with high levels of HBx protein are found in transgenic mice 4 months after birth, and by months 8–10, the altered hepatocytes have developed into adenomas that expressed high levels of HBx protein (Wang et al., 2012c). HBx can induce intrinsic cellular transformation, as well as promoting expansion and tumorigenicity in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated (DDC) HBx transgenic mice (Lu et al., 2012). Some antioxidant enzymes, such as glutathione peroxidase and superoxide dismutase 2, are down-regulated in HBV transgenic mice and correlate with JNK activation. HBV can enhance the Fas-mediated activation of caspase-6, caspase-8 and JNK without enhancing activation of caspase-3 and apoptosis (Wang et al., 2012a). Dysregulation of apoptosis facilitates the escape of abnormal cells from death, suggesting a mechanism by which HBV promotes HCC (Barone et al., 2006). A humanized mouse model

made by reconstitution of human primary hepatocytes in the liver of an immunodeficient mouse provides novel experimental opportunities because this model mimics the *in vivo* growth of human hepatocytes and thus facilitating the direct investigation of HBV and HCC (Zhou et al., 2012) (Fig. 4).

4.2. Chimpanzee models

Chimpanzees have served as a model for studying HBV infection for 20 years. Between 3 and 6% of wild-caught chimpanzees are positive for HBsAg, a marker of chronic HBV infection, and as many as 50% are positive for antibodies against HBsAg (anti-HBs), a marker of resolved infection (Vartanian et al., 2002). The HBVs isolated from 11 of 13 chimpanzees with chronic infections appear to be genetically distinct from known human HBV genotypes and appear to represent viruses that produce an infection indigenous to chimpanzees (Hu et al., 2000). Compared with HBV isolated from other primates, the chimpanzee HBV has unique nucleotide and amino acid changes throughout the entire genome; the S gene may allow rapid and precise identification of this strain (MacDonald et al., 2000). This occurrence demonstrates that despite their genetic divergence, human and non-human associated variants of HBV may share hosts in nature. A recent study characterizing HBV variants infecting chimpanzee populations has demonstrated the existence of a novel HBV strain and evidence of recombination between HBV strains circulating in chimpanzees (Sa-Nguanmoo et al., 2009). The S-gene mutant readily reverted back to the wild-type sequence but the Pol-gene mutant was stable during the course of infection (Magiorinis et al., 2005). Vaccination of naive chimpanzees with a commercial hepatitis B vaccine resulted in the induction of cellular immune responses but did not appear to confer sterilizing immunity against challenge with the Pol-gene mutant and subsequent challenge with a serum-derived wt-HBV (Lyons et al., 2012) (Fig. 4).

4.3. Woodchuck models

Woodchuck hepatitis virus (WHV) has been used extensively in the modeling of HBV infection and antiviral therapy (Roggendorf et al., 2010). Since 1988, the neonatal chronic WHV infection model has been used primarily to test antiviral nucleoside analogs in chronic HBV infection. The focus of investigations using the woodchuck model has ranged widely, with flexible emphasis on both model development and application in many areas of HBV research, including viral and disease pathogenesis, prevention and treatment of HBV infection, disease sequelae (including HCC) using vaccines, antiviral drugs, and immunomodulators alone and in combination (Korba et al., 2000) (Fig. 4).

4.4. Tree shrews models

Tree shrews, the lowest order of non-human primates, can be used as a reliable and useful animal model for research on HBV infection as well as its relation to HCC (Yang et al., 2005). Tree shrews can be experimentally infected with HBV by inoculation with HBV-positive human serum. The transmission of HBV into tree shrews by inoculation with HBV-positive tree shrew serum is more effective than primary inoculation with HBV-positive human serum. Additionally, successive infections have been passed down through five generations of tree shrews inoculated with HBV-positive sera from an infected animal (Ren and Nassal, 2001). The experimental infection of tree shrews with HBV may be prevented by immunization with a hepatitis B vaccine, which is similar to the results in human studies (Wang et al., 2012d) (Fig. 4).




Fig. 4. *In vivo* animal models of HBV.

5. Therapeutic applications in HBV

5.1. HBV diagnosis and prevention

The diagnosis of HBV infection and its associated diseases is based upon a constellation of clinical, biochemical, histological, and serologic findings (Dufour et al., 2000). Many viral antigens and their respective antibodies can be detected in serum after HBV infection, and proper interpretation of the results is essential for the correct diagnosis of the various clinical forms of HBV infection (Kao, 2008). Increased HBV viral level is a risk predictor for the development of cirrhosis and HCC (Liang and Ghany, 2002). Levels of hepatic cccDNA may provide a greater predictive value of response to clinical therapies than alternative measures. Sensitive assays are available that can detect resistant viral variants during therapy before an increase in HBV-DNA level. The method for HBV genotype determination is sequencing followed by phylogenetic analysis of the generated sequences with reference sequences (Ganova-Raeva et al., 2012). Furthermore, detection of GzmH levels may be a potential parameter for the diagnosis of HBV and HCC because low GzmH expression in cytotoxic lymphocytes has

been observed in individuals susceptible to HBV infection and HCC (Bosch et al., 2004).

HBV vaccines are HBsAg-based and their protective efficacy is mediated by neutralizing antibodies, which block HBV from entering hepatocytes (Francois et al., 2005). Active prophylaxis against HBV infection is available in the form of a recombinant HBV vaccine. The commercial products available are Recombivax HB and Engerix-B, both of which are highly effective in producing antibodies (Fitzsimons et al., 2005; Rapicetta et al., 2009). In addition, passive immunization is available by pooling serum from patients who have recovered spontaneously from acute HBV and have significant anti-HBs concentration (Chunsuttiwat et al., 2002).

5.2. Current HBV therapeutic drugs

The HBV polymerase has been the main target of anti-HBV drug development. The FDA has licensed two types of drugs to treat HBV infection: two formulations of interferons and five nucleos(t)ide analogs (lamivudine, adefovir, entecavir, telbivudine, and tenofovir) (see in Table 1).

Table 1
Approved and ongoing anti-HBV therapeutic agents.

Mechanism	Aim at HBV		Aim at host
	Inhibition of the peptides processing way	Inhibition of HBV replication	Immune regulation targets
Target	HBx, HBeAg	Inhibits viral DNA polymerase	HBV Core Antigen
Approved drugs	NOV-205 (Approved in Russia)	Lamivudine, Adefovir Dipivoxil, Entecavir, Telbivudine, Tenofovir, Clevudine	Interferon- α Peginterferon- α 2a
Phase III		Emtricitabine	
Phase II	LB80380 (ANA380)	MIV-210	IFN- λ (Phase I/II)
Phase I	Valtorcitabine (Phase I/II) (Sweden)	Elvucitabine (Phase I/II)	REP 9AC (Phase I/II)
	Valtorcitabine (Phase I/II) (Sweden)	Elvucitabine (Phase I/II) Myrcludex-B Pradefovir	IFN- λ (Phase I/II) DV-601 REP 9AC (Phase I/II)

5.2.1. Interferons

IFNs, binding to receptors on cell membranes, are naturally occurring cytokines that act as immunomodulatory, anti-proliferative and antiviral reagents. IFN- α has been approved for HBV treatment, but this interferon requires three injections every week and, unfortunately, has limited treatment success (Janssen et al., 2005). The addition of a polyethylene glycol (PEG) molecule to the IFN extends the half-life of drug and prolongs IFN activity, resulting in an increase in the incidence of HBeAg and HBsAg seroconversion (van Zonneveld et al., 2004). Over the last few years, clinical research has focused on the use of peginterferon (PEG-IFN) administered by injection on a weekly basis and peginterferon- α -2a has been licensed for the treatment of chronic HBV infection (Hayashi et al., 2007).

5.2.2. Nucleos(t)ide analogs

Lamivudine, the first nucleoside analog licensed in 1998, is given in a dosage of 100 mg daily and generally results in normal ALT levels and undetectable HBV DNA in HBeAg-positive patients (50–80%) and HBeAg-negative patients (20–25%) (Liau et al., 2004). Besides, lamivudine leads to resistance at a rate of approximately 20% of patients per year and then reaches 65–70% after 4–5 years of therapy. Adefovir can incorporate diphosphates into the replicating viral DNA, causes premature DNA chain termination, associated with a 12% rate of HBeAg seroconversion, 21% rate of undetectable serum HBV DNA and 53% rate of improvement in HBeAg-positive patients after 1 year of therapy (Fung et al., 2006). However, resistance becomes a limiting factor with prolonged use and has been demonstrated at 1, 2, 4 and 5 years at a rate of 0%, 3%, 18% and 29%, respectively (Yuen and Lai, 2004). Entecavir is a guanosine nucleoside analog that has selective activity against HBV by competing with the natural substrate deoxyguanosine triphosphate and inhibiting the activities of HBV polymerase (Colonno et al., 2006). Early studies suggested that entecavir-treated patients had a more sustained response to the drug, even after treatment ended, and even in patients with HBeAg-negative HB (Sherman et al., 2008). The cumulative probability of entecavir resistance at years 1 through 5 is 6%, 15%, 36%, 46% and 51%, respectively. Telbivudine is a nucleoside analog that suppresses viral load and decreases liver inflammation; the analog is easily phosphorylated in the body to the active triphosphate form (Lai et al., 2007). The overall rate of telbivudine resistance is 22% in patients with HBeAg-positive CHB and 9% in those with HBeAg-negative CHB. Tenofovir is a methyl derivative of adefovir and exhibits anti-viral activity against lamivudine-resistant HBV, similar to adefovir (van Bömmel et al., 2006). Tenofovir has been shown to be more potent than adefovir in achieving viral suppression defined as histological improvement (67%) and higher rates of HBsAg loss (3.2%) at 48 weeks in patients with HBeAg-positive CHB.

Some adverse effects do exist for current HBV drugs. The side effects of pegylated interferon include flu-like symptoms, marrow suppression, depression and anxiety, as well as autoimmune disorders (Lee et al., 2012). The disadvantages of lamivudine include the high incidence of antiviral resistance and high risk of relapse after discontinuation of therapy (Dienstag et al., 2003). The major adverse effects of long-term administration of nucleotide or nucleoside RT inhibitors are nephrotoxicity and myopathy (Fleischer and Lok, 2009). Nephrotoxicity is characterized by a gradual increase in serum creatinine and a decrease in serum phosphorus due to the inhibition (or toxicity) of kidney function. At high doses, adefovir and tenofovir have been reported to be associated with nephrotoxicity in chronic hepatitis B patients (Zoulim and Locarnini, 2009). In addition, myopathy characterized by muscle pain, weakness or tenderness can be observed in patients who have received long-term treatment with telbivudine (Delaney et al., 2006).

5.3. Current HBV drugs

Several novel drugs can inhibit the reverse transcription involved in HBV DNA replication for both wild-type and drug-resistant HBV. Lagociclovir valactate (MIV-210) is a prodrug with high oral bioavailability in humans and potent activity against hepatitis B virus (Michalak et al., 2009). Elvucitabine is a nucleoside analog RT inhibitor that showed strong anti-HBV activity in an *in vitro* trial for treatment of chronic HBV (Zhu et al., 1998). Additionally, Valtorcitabine, a well-absorbed prodrug of L-deoxycytidine, has been shown to suppress serum HBV DNA in HBeAg-positive patients (Iino et al., 2005). Emtricitabine, which is similar in structure, efficacy and resistance profile to lamivudine, appears to confer no advantage over lamivudine, while clevudine is distinguished from other oral agents by its sustained suppression of HBV DNA (Lim et al., 2006; Saniova et al., 2006). The entry inhibitor Myrcludex-B can prevent the spread of HBV from infected human hepatocytes *in vivo* and hinder amplification of the cccDNA pool in initially infected hepatocytes (Volz et al., 2012). A cyclic 1-aryl-1, 3-propanyl prodrug of adefovir dipivoxil, Pradefovir, has been developed to avoid much of the renal toxicity of adefovir dipivoxil (Li et al., 2008). Besifovir (LB80380) is a potent oral nucleotide prodrug with a chemical structure similar to that of adefovir and tenofovir, and an *in vitro* study showed that besifovir was effective against HBV strains resistant to lamivudine, adefovir dipivoxil, entecavir, and telbivudine (Yuen et al., 2009).

Some non-nucleoside anti-HBV agents are being developed, and a number of these inhibitors targeting viral antigens or replication have been tested in hepatitis-related cells. REP 9AC is a nucleic acid-based amphipathic polymer that belongs to a new class of anti-viral compounds based on the sequence-independent activity of phosphorothioated oligonucleotides (Wu et al., 2009). REP

9AC facilitates innate immunity against HBV by inhibiting release of subviral particles, including HBsAg, from infected hepatocytes. IFN- λ , with similar biological characteristics to IFN- α and IFN- β , can inhibit HBV replication by preventing the assembly of viral RNA-containing capsids in the cytoplasm (Robek et al., 2005).

5.4. Combination therapeutic strategies

Combination therapies of adefovir and entecavir demonstrated faster and greater suppression of HBV DNA compared to adefovir add-on lamivudine combination therapies for patients with lamivudine-resistance mutations. The former combination therapy was superior to the latter for both initial virological response and long-term suppression activity against HBV. Adefovir and entecavir combination therapies are most effective at discouraging selection of HBV strains that are cross-resistant in LAM-resistance patients (Momin and Richardson, 2012). Extended combination therapy with lamivudine and adefovir is associated with a high rate of long-term virological and biochemical responses (Lai et al., 2005). Similarly, telbivudine and lamivudine in combination cannot achieve additional anti-viral activity over that of telbivudine alone (Akyildiz et al., 2007). Combination therapeutics with agents of differing resistance profiles should limit the emergence of resistance. Resistance is negligible during the early years of treatment with entecavir or tenofovir, demonstrating the superiority of preemptive combination therapies over initial mono-therapy. A complementary drug added after the emergence of viral resistance has been another therapeutic strategy.

6. Conclusions and future perspectives

HBV infection is one of the most important causes of human liver disease, and substantial data have explored the complicated mechanisms of HBV replication and infection and several key modulators in HBV and HCC, as well as genomic factors (e.g., microRNAs, genotypes and SNPs) and epigenetic regulation, all of which may be integrated to form systematically the complicated HBV regulation network. Moreover, *in vivo* models of HBV have been developed for further elucidation of the infection mechanisms of HBV, thus providing new clues for exploiting potential novel diagnostics and preventive or therapeutic drugs against HBV. Currently, there is increasing evidence of the importance of profound, durable therapeutic HBV DNA suppression to slow and reverse HBV infection with the aid of FDA-approved drugs such as interferon alpha, pegylated interferon alpha-2a, lamivudine, adefovir, entecavir, telbivudine, and tenofovir.

The best hope for HBV therapy may lie in discovering novel candidate drugs aimed at the “Achilles heel” of HBV, namely, core regulatory pathways or even the entire network, rather than individual gene or protein components (single target). The next generation of HBV drug discovery should target the HBV network (multi-targets). In summary, a Herculean effort will have to be mounted to explore the intricate mechanisms and novel therapeutic strategies for HBV. Thus, we expect anti-HBV drug regimens to improve in efficacy without engendering resistance and hope that combination therapeutics and even multi-target approaches will make great contributions and address future problems.

Acknowledgements

This work was supported by grants from the National 973 Basic Research Program of China (Nos. 2013CB911300, 2010CB529900 and 2012CB518900), National Natural Science Funds for Distinguished Young Scholar (No. 81225015), Key Projects of the National Science and Technology Pillar Program

(No. 2011BAZ02590), the National Science and Technology Major Project (No. 2012ZX09501001-003), and National Natural Science Foundation of China (Nos. 81260628 and 81202403).

References

- Akyildiz M, Gunsar F, Ersoz G, Karasu Z, Ilter T, Batur Y, et al. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. *Digestive Diseases and Sciences* 2007;52:3444–7.
- Almajhdi FN, Al-Ahdal M, Abdo AA, Sanai FM, Al-Anazi M, Khalaf N, et al. Single nucleotide polymorphisms in CXCR1 gene and its association with hepatitis B infected patients in Saudi Arabia. *Annals of Hepatology* 2013;12:220–7.
- Al-Qahtani A, Alarif S, Al-Okail M, Hussain Z, Abdo A, Sanai F, et al. RANTES gene polymorphisms (–403G>A and –28C>G) associated with hepatitis B virus infection in a Saudi population. *Genetics and Molecular Research* 2012;11:855–62.
- Bardens A, Drink T, Stieler J, Prange R. Alix regulates egress of hepatitis B virus naked capsid particles in an ESCRT-independent manner. *Cellular Microbiology* 2011;13:602–19.
- Barone M, Spano D, D'Apolito M, Centra M, Lasalandra C, Capasso M, et al. Gene expression analysis in HBV transgenic mouse liver: a model to study early events related to hepatocarcinogenesis. *Molecular Medicine* 2006;12:115–23.
- Beck J, Nassal M. Hepatitis B virus replication. *World Journal of Gastroenterology* 2007;13:48–64.
- Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. *JAMA* 1965;191:541–6.
- Bosch FX, Ribes J, Diaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. *Gastroenterology* 2004;127:S5–16.
- Braconi C, Patel T. MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. *Hepatology* 2008;47:1807–9.
- Carlson CS, Eberle MA, Rieder MJ, Smith JD, Kruglyak L, Nickerson DA. Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. *Nature Genetics* 2003;33:518–21.
- Chen J, Wang L, Li Y, Cai B, Fu Y, Liao Y, et al. Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese. *PLoS ONE* 2012;7:e50787.
- Chen J, Yin J, Tan X, Zhang H, Zhang H, Chen B, et al. Improved multiplex-PCR to identify hepatitis B virus genotypes A-F and subgenotypes B1, B2, C1 and C2. *Journal of Clinical Virology* 2007;38:238–43.
- Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Research* 2008;18:997–1006.
- Cheng HR, Liu CJ, Tseng TC, Su TH, Yang HI, Chen CJ, et al. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. *PLoS ONE* 2013;8:e53008.
- Chisari F, Klopchin K, Morijama T, Pasquinelli C, Dunsford HA, Sell S, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. *Cell* 1989;59:1145–56.
- Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. *Hepatology* 2002a;36:1408–15.
- Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. *Hepatology* 2002b;35:1274–6.
- Chunsubtiwat S, Biggs BA, Maynard JE, Thammapornpilas P, O-Prasertsawat M. Comparative evaluation of a combined DTP-HB vaccine in the EPI in Chiangrai Province, Thailand. *Vaccine* 2002;21:188–93.
- Colonna RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. *Hepatology* 2006;44:1656–65.
- Cougot D, Allemand E, Rivière L, Benhenda S, Duroure K, Levillayer F, et al. Inhibition of PP1 phosphatase activity by HBx: a mechanism for the activation of hepatitis B virus transcription. *Signal Transduction* 2012;5:ra1.
- Dandri M, Burda MR, Burkle A, Zuckerman DM, Will H, Rogler CE, et al. Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly (ADP-ribosyl)ation. *Hepatology* 2002;35:217–23.
- Delaney WEJ4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, et al. Intracellular metabolism and *in vitro* activity of tenofovir against hepatitis B virus. *Antimicrobial Agents and Chemotherapy* 2006;50:2471–7.
- Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. *Gastroenterology* 2003;124:105–17.
- Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. *Clinical Chemistry* 2000;46:2027–49.
- Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. *Journal of Hepatology* 2008;48:335–52.
- Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. *Cancer Letters* 2007;253:157–70.
- Fitzsimons D, Francois G, Hall A, McMahon B, Meheus A, Zanetti A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. *Vaccine* 2005;23:4158–66.
- Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. *Journal of Hepatology* 2009;51:787–91.

- Francois G, Duclos P, Margolis H, Lavanchy D, Siegrist CA, Meheus A, et al. Vaccine safety controversies and the future of vaccination programs. *Pediatric Infectious Disease Journal* 2005;24:953–61.
- Fu LL, Wen X, Bao JK, Liu B. MicroRNA-modulated autophagic signaling networks in cancer. *International Journal of Biochemistry and Cell Biology* 2012;44:733–6.
- Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. *Journal of Hepatology* 2006;44:283–90.
- Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in *E. coli*. *Nature* 1979;281:646–50.
- Ganem D, Prince AM. Hepatitis B virus infection – natural history and clinical consequences. *New England Journal of Medicine* 2004;350:1118–29.
- Ganova-Raeva L, Ramachandran S, Honisch C, Zhang H, Fan Z. Granzyme H of cytotoxic lymphocytes is required for clearance of the hepatitis B virus through cleavage of the hepatitis B virus X protein. *Journal of Immunology* 2012;188:824–31.
- Gao B, Wang H, Lafdil F, Feng D. STAT proteins-key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. *Journal of Hepatology* 2012;57:430–41.
- Hayashi K, Katano Y, Takeda Y, Honda T, Ishigami M, Itoh A, et al. Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. *Journal of Medical Virology* 2007;79:366–73.
- Heindryckx F, Colle I, Vlierbergh HV. Experimental mouse models for hepatocellular carcinoma research. *International Journal of Experimental Pathology* 2009;90:367–86.
- Hofmeyer KA, Jeon H, Zang X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. *Journal of Biomedicine and Biotechnology* 2011;2011:451694.
- Hu X, Margolis HS, Purcell RH, Ebert J, Robertson BH. Identification of hepatitis B virus indigenous to chimpanzees. *Proceedings of the National Academy of Sciences of the United States of America* 2000;97:1661–4.
- Huang Y, Tong S, Tai AW, Hussain M, Lok AS. Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. *Gastroenterology* 2011;141:1412–21.
- Iino S, Toyota J, Kumada H, Kiyosawa K, Kakumu S, Sata M, et al. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. *Journal of Viral Hepatitis* 2005;12:300–6.
- Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed. *Liver International* 2012;32:1333–41.
- Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. *Lancet* 2005;365:123–9.
- Kann M, Schmitz A, Rabe B. Intracellular transport of hepatitis B virus. *World Journal of Gastroenterology* 2007;13:39–47.
- Kao JH. Diagnosis of hepatitis B virus infection through serological and virological markers. *Expert Review of Gastroenterology and Hepatology* 2008;2:553–62.
- Kim JS, Rho B, Lee TH, Lee JM, Kim SJ, Park JH. The interaction of hepatitis B virus X protein and protein phosphatase type 2 Calpha and its effect on IL-6. *Biochemical and Biophysical Research Communications* 2006;351:253–8.
- Kim SY, Lee PY, Shin HJ, Kim do H, Kang S, Moon HB, et al. Proteomic analysis of liver tissue from HBx-transgenic mice at early stages of hepatocarcinogenesis. *Proteomics* 2009;9:5056–66.
- Knoll S, Fürst K, Thomas S, Villanueva Baselga S, Stoll A, Schaefer S, et al. Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC. *Cell Cycle* 2011;10:3554–65.
- Korba BE, Cote P, Hornbuckle W, Tennant BC, Gerin JL. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (*Marmota monax*) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. *Hepatology* 2000;31:1165–75.
- Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. *Hepatology* 2008;47:1955–63.
- Lai CL, Gane E, Liaw YE, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. *New England Journal of Medicine* 2007;357:2576–88.
- Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. *Gastroenterology* 2005;129:528–36.
- Lakner AM, Bonkovsky HL, Schrum LW. microRNAs: fad or future of liver disease. *World Journal of Gastroenterology* 2011;17:2536–42.
- Lee DK, Park SH, Yi Y, Choi SG, Lee C, Parks WT, et al. The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. *Genes and Development* 2001;15:455–66.
- Lee JH, Yoon JH, Cho EJ, Yang HJ, Jang ES, Kwak MS, et al. Simple scoring system predicting genotypic resistance during rescue therapy for lamivudine-resistant chronic hepatitis B. *Journal of Clinical Gastroenterology* 2012;46:243–50.
- Li F, Maag H, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. *Journal of Pharmaceutical Sciences* 2008;97:1109–34.
- Liang TJ, Ghany M. Hepatitis B. e Antigen—the dangerous endgame of hepatitis B. *New England Journal of Medicine* 2002;347:208–10.
- Liang TJ. Hepatitis B: the virus and disease. *Expert Review of Anti-infective Therapy* 2009;7:309–20.
- Liaw YF, Chu CM. Hepatitis B virus infection. *Lancet* 2009;373:582–92.
- Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *New England Journal of Medicine* 2004;351:1521–31.
- Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. *Archives of Internal Medicine* 2006;166:49–56.
- Liu Y, Tong Z, Li T, Chen Q, Zhuo L, Li W, et al. Hepatitis B virus X protein stabilizes amplified in breast cancer 1 protein and cooperates with it to promote human hepatocellular carcinoma cell invasiveness. *Hepatology* 2012a;56:1015–24.
- Liu H, Yuan Y, Guo H, Mitchelson K, Zhang K, Xie L, et al. Hepatitis B virus encoded X protein suppresses apoptosis by inhibition of the caspase-independent pathway. *Journal of Proteome Research* 2012b;11:4803–13.
- Lu JW, Hsia Y, Yang WY, Lin YI, Li CC, Tsai TF, et al. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. *Carcinogenesis* 2012;33:209–19.
- Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. *Journal of Hepatology* 2011;55:996–1003.
- Lutgehetmann M, Volz T, Kopke A, Broja T, Tigges E, Lohse AW, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. *Hepatology* 2010;52:16–24.
- Lyons S, Sharp C, LeBreton M, Djoko CF, Kiyang JA, Lankester F, et al. Species association of hepatitis B virus (HBV) in non-human apes; evidence for recombination between gorilla and chimpanzee variants. *PLoS ONE* 2012;7:e33430.
- Ma J, Sun T, Park S, Liu J. The role of hepatitis B virus X protein is related to its differential intracellular localization. *Acta Biochimica et Biophysica Sinica (Shanghai)* 2011;43:583–8.
- MacDonald DM, Holmes EC, Lewis JC, Simmonds P. Detection of hepatitis B virus infection in wild-born chimpanzees (*Pan troglodytes verus*): phylogenetic relationships with human and other primate genotypes. *Journal of Virology* 2000;74:4253–7.
- Magiorkinis EN, Magiorkinis GN, Paraskevis DN, Hatzakis AE. Re-analysis of a human hepatitis B virus (HBV) isolate from an East African wild born *Pan troglodytes schweinfurthii*: evidence for interspecies recombination between HBV infecting chimpanzee and human. *Gene* 2005;349:165–71.
- Mason WS, Jilbert AR, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. *Proceedings of the National Academy of Sciences of the United States of America* 2005;102:1139–44.
- Michalak TI, Zhang H, Churchill ND, Larsson T, Johansson NG, Oberg B. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. *Antimicrobial Agents and Chemotherapy* 2009;53:3803–14.
- Momin B, Richardson L. An analysis of content in comprehensive cancer control plans that address chronic hepatitis B and C virus infections as major risk factors for liver cancer. *Journal of Community Health* 2012;37:912–6.
- Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. *Journal of Gastroenterology* 2001;36:651–60.
- Neurath AR, Kent SB, Strick N. Detection of antiviral antibodies with predetermined specificity using synthetic peptide-beta-lactamase conjugates: application to antibodies specific for the preS region of the hepatitis B virus envelope proteins. *Journal of General Virology* 1986;67:453–61.
- Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. *Journal of Virology* 1995;69:3350–7.
- Ng LF, Chan M, Chan SH, Cheng PC, Leung EH, Chen W, et al. Host heterogeneous ribonucleoprotein K (hnRNPK) as a potential target to suppress hepatitis B virus replication. *PLoS Medicine* 2005;2:e163.
- Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. *Hepatology* 2001;33:218–23.
- Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. *Nature* 2007;449:919–22.
- Perlman D, Hu J. Duck hepatitis B virus virion secretion requires a double-stranded DNA genome. *Journal of Virology* 2003;77:2287–94.
- Protzer U, Seyfried S, Quasdorff M, Sassi G, Svorcova M, Webb D, et al. Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. *Gastroenterology* 2007;133:1156–65.
- Qadri I, Fatima K, Abdel-Hafiz H. Hepatitis B virus X protein impedes the DNA repair via its association with transcription factor, TFIIH. *BMC Microbiology* 2011;11:48.
- Rahmani Z, Huh KW, Lasher R, Siddiqui A. Hepatitis B virus X protein localizes to mitochondria with a human voltage-dependent anion channel HVDAC3, and alters its transmembrane potential. *Journal of Virology* 2000;74:2840–6.
- Rapicetta M, D'Ugo E, Argentini C, Catone S, Canitano A, Giuseppetti R, et al. New perspectives for hepatitis B vaccines and immunization. *Vaccine* 2009;27:3271–5.
- Ren S, Nassal M. Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors. *Journal of Virology* 2001;75:1104–6.
- Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. *Journal of Virology* 2005;79:3851–4.

- Roggendorf M, Yang D, Lu M. The woodchuck: a model for therapeutic vaccination against hepadnaviral infection. *Pathologie Biologie* 2010;58:308–14.
- Sa-Nguanmoo P, Rianthavorn P, Amornsawadwattana S, Poovorawan Y. Hepatitis B virus infection in non-human primates. *Acta Virologica* 2009;53:73–82.
- Saniova B, Drobny M, Lehotsky J, Sulaj M, Schudichova J. Biochemical and clinical improvement of cytotoxic state by amantadine sulphate. *Cellular and Molecular Neurobiology* 2006;26:1475–82.
- Schmitt S, Glebe D, Alving K, Lochnit G, Linder D, Geyer R. Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. *Journal of Biological Chemistry* 1999;274:11945–57.
- Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. *Science* 1986;232:477–84.
- Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. *Hepatology* 2008;48:99–108.
- Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. *Hepatology* 2003;37:19–26.
- Sung WK, Lu Y, Lee CW, Zhang D, Ronaghi M, Lee CG. Dereglated direct targets of the hepatitis B virus (HBV) protein, HBx, identified through chromatin immunoprecipitation and expression microarray profiling. *Journal of Biological Chemistry* 2009;284:21941–54.
- Tang H, Da L, Mao Y, Li Y, Li D, Xu Z, et al. Hepatitis B virus X protein sensitizes cells to starvation-induced autophagy via up-regulation of beclin 1 expression. *Hepatology* 2009;49:60–71.
- Tong AP, Gou LT, Lau QC, Chen B, Zhao X, Li J, et al. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein. *Journal of Proteome Research* 2009;8:1037–46.
- Truelove AL, Oleksyk TK, Shrestha S, Thio CL, Goedert JJ, Donfield SM, et al. Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. *International Journal of Immunogenetics* 2008;35:255–64.
- Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. *Journal of Hepatology* 2010;52:282–4.
- Valenzuela P, Gray P, Quiroga M, Zaldivar J, Goodman HM, Rutter WJ. Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. *Nature* 1979;280:815–9.
- van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. *Hepatology* 2006;44:318–25.
- van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. *Hepatology* 2004;39:804–10.
- Vartanian JP, Pineau P, Henry M, Hamilton WD, Muller MN, Wrangham RW, et al. Identification of a hepatitis B virus genome in wild chimpanzees (*Pan troglodytes schweinfurthi*) from East Africa indicates a wide geographical dispersion among equatorial African primates. *Journal of Virology* 2002;76:11155–8.
- Vivekanandan P, Thomas D, Torbenson M. Methylation regulates hepatitis B viral protein expression. *Journal of Infectious Diseases* 2008;199:1286–91.
- Volz T, Allweiss L, Berek MB, Warlich M, Lohse AW, Pollok JM, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with Hepatitis B virus. *Journal of Hepatology* 2012; pii: S0168-8278(12)00956-7.
- Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. *Hepatology* 2009;50:1152–61.
- Wang C, Yang W, Yan HX, Luo T, Zhang J, Tang L, et al. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. *Hepatology* 2012a;55:108–20.
- Wang F, Zhou H, Yang Y, Xia X, Sun Q, Luo J, et al. Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. *Oncology Reports* 2012b;27:1170–6.
- Wang HY, Chien MH, Huang HP, Chang HC, Wu CC, Chen PJ, et al. Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. *Journal of Virology* 2010a;84:3454–63.
- Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB upregulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. *Nucleic Acids Research* 2010b;38:5366–83.
- Wang P, Guo QS, Wang ZW, Qian HX. HBx induces HepG-2 cells autophagy through PI3K/Akt-mTOR pathway. *Molecular and Cellular Biochemistry* 2013;372:161–8.
- Wang Q, Na B, Ou JH, Pulliam L, Yen TSB. Hepatitis B virus alters the antioxidant system in transgenic mice and sensitizes hepatocytes to fas signaling. *PLoS ONE* 2012c;7:e36818.
- Wang Q, Schwarzenberger P, Yang F, Zhang J, Su J, Yang C, et al. Experimental chronic hepatitis B infection of neonatal tree shrews (*Tupaia belangeri chinensis*): A model to study molecular causes for susceptibility and disease progression to chronic hepatitis in humans. *Journal of Virology* 2012d;9:170.
- Wang Y, Xu P, Zhu D, Zhang S, Bi Y, Hu Y, et al. Association of polymorphisms of cytokine and TLR-2 genes with long-term immunity to hepatitis B in children vaccinated early in life. *Vaccine* 2012e;30:5708–13.
- Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. *Hepatology* 2009;49:1132–40.
- Xia L, Tian D, Huang W, Wang J, Zhang Y, Hu H, et al. Upregulation of IL-23 expression in patients with chronic hepatitis B is mediated by the HBx/ERK/NF- κ B pathway. *Journal of Immunology* 2012;188:753–64.
- Xie J, Zhang Y, Zhang Q, Yin J, Pu R, Shen Q, et al. Interaction of signal transducer and activator of transcription 3 polymorphisms with HBV mutations in hepatocellular carcinoma. *Hepatology* 2013. <http://dx.doi.org/10.1002/hep.26302>.
- Xie N, Huang K, Zhang T, Lei YL, Liu R, Wang K, et al. Comprehensive proteomic analysis of host cell lipid rafts modified by HBV infection. *Journal of Proteomics* 2012;75:725–39.
- Xu J, Liu H, Chen L, Wang S, Zhou L, Yun X, et al. Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1. *Gastroenterology* 2012;143:199–212.
- Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. *Elife* 2012;1:e00049.
- Yang EB, Cao J, Su JJ, Chow P. The tree shrews: useful animal models for the viral hepatitis and hepatocellular carcinoma. *Hepato-Gastroenterology* 2005;52:613–6.
- Yuen MF, Lai CL. Adefovir dipivoxil in chronic hepatitis B infection. *Expert Opinion on Pharmacotherapy* 2004;5:2361–7.
- Yuen MF, Lee SH, Kang HM, Kim CR, Kim J, Ngai V, et al. Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. *Antimicrobial Agents and Chemotherapy* 2009;53:1779–85.
- Zhang T, Xie N, He WF, Liu R, Lei YL, Chen Y, et al. An integrated proteomics and bioinformatics analyses of Hepatitis B Virus X protein and identification of a novel interactor apoA-I. *Journal of Proteomics* 2013;84:92–105.
- Zhang X, Hong X, Deng G, Bai X. Single nucleotide polymorphisms and functional analysis of class II transactivator (CIITA) promoter IV in persistent HBV infection. *Journal of Clinical Virology* 2007;40:197–201.
- Zhang Z, Sun E, Ou JH, Liang TJ. Inhibition of cellular proteasome activities mediates HBx-independent hepatitis B virus replication in vivo. *Journal of Virology* 2010;84:9326–31.
- Zhou J, Smith DK, Lu L, Poon VK, Ng F, Chen DQ, et al. A non-synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection. *Journal of Viral Hepatitis* 2009;16:45–52.
- Zhou XL, Sullivan GJ, Sun P, Park IH. Humanized murine model for HBV and HCV using human induced pluripotent stem cells. *Archives of Pharmacological Research* 2012;35:261–9.
- Zhu YL, Dutschman DE, Liu SH, Bridges EG, Cheng YC. Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine. *Antimicrobial Agents and Chemotherapy* 1998;42:1805–10.
- Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. *Journal of Hepatology* 2005;42:302–8.
- Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. *Gastroenterology* 2009;137:1593–608.